NovoCure NVCR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$173.05M-5.4% | -$136.23M+19.2% | -$177.65M-18.6% | -$170.95M-1.3% | -$164.19M+14.8% | ||
| $15.45M+31.5% | $14.65M+30.4% | $13.54M+24.7% | $12.33M+10.1% | $11.75M+6.2% | ||
| $138.29M-11.1% | $104.83M-34.5% | $147.77M+28.8% | $149.82M+36.6% | $155.5M+40.6% | ||
| $3.3M+2.4% | $4.85M+319% | $3.29M+264% | $3.51M+521% | $3.23M+475% | ||
| $4.51M+237% | $5.67M+321% | $249K-83.8% | -$760K-110% | -$3.28M-130% | ||
| $30.26M+44.6% | $18.96M-0.8% | $30.87M+75.2% | $13.49M-17.9% | $20.93M+195% | ||
| $7M+254% | $4.95M+860% | $3.73M+759% | $1.72M+52.7% | -$4.54M-272% | ||
| -$10.31M-10.0% | -$10.85M-36.1% | -$6.48M+23.4% | -$5.9M+44.0% | -$9.37M-153% | ||
| -$6.99M-22.3% | -$5.27M+17.1% | -$3.86M+44.7% | -$2.97M+65.2% | -$5.72M+31.9% | ||
| -$19.23M+28.6% | -$23.26M+9.3% | -$26.19M+0.2% | -$26.52M-1.3% | -$26.92M-10.3% | ||
| -$26.88M+11.7% | -$49.03M-85.9% | -$34.48M+8.0% | -$44.68M+33.5% | -$30.46M+65.5% | ||
| $21.19M-49.2% | $26.65M-37.8% | $30.69M-24.6% | $35.72M-4.2% | $41.68M+27.1% | ||
| $1.28B+99.2% | $1.29B+65.2% | $895M-1.3% | $900M-9.3% | $640M-44.2% | ||
| $802.32M-19.1% | $821.08M-6.2% | $785.57M-11.3% | $846.78M-12.5% | $991.25M+29.4% | ||
| $451.5M+215% | $437.28M+412% | $78.74M+503% | $17.5M+240% | -$392.93M-213% | ||
| $99.98M+3.2% | $99.98M+3.2% | $99.98M+3.2% | $0-100% | $96.92M— | ||
| $560.95M+4,244% | $560.95M+4,244% | $0-100% | $0-100% | $12.91M+430,333% | ||
| $3.66M-11.9% | $3.66M-11.9% | $4.1M+10.2% | $4.1M+10.2% | $4.15M-6.0% | ||
| -$456.76M-579% | -$451.34M-600% | $110.84M+23.8% | $10.42M-88.5% | $95.35M+783% | ||
| —— | —— | $342K+122% | $451K+1,603% | $109K+221% | ||
| -$32.11M+90.2% | -$62.7M+18.0% | $155.44M+376% | -$16.31M-249% | -$327.93M-221% | ||
| $15.72M+51.8% | $13.41M+73.8% | $10.94M+122% | $11.06M+460% | $10.36M+147,857% | ||
| $21.83M-14.5% | $30.67M+30.7% | $28.65M+30.4% | $31.86M+92.6% | $25.52M+71.6% | ||
| -$19.23M+28.6% | -$23.26M+9.3% | -$26.19M+0.2% | -$26.52M-1.3% | -$26.92M-10.3% | ||
| $3.3M+2.4% | $4.85M+319% | $3.29M+264% | $3.51M+521% | $3.23M+475% | ||
| —— | —— | -$1.22M— | $171K— | $889K— | ||
| $29.5M-6.9% | $38.94M+47.7% | $32.85M+797% | $31.02M+382% | $31.69M+373% | ||
| $7M+254% | $4.95M+860% | $3.73M+759% | $1.72M+52.7% | -$4.54M-272% | ||
| -$6.99M-22.3% | -$5.27M+17.1% | -$3.86M+44.7% | -$2.97M+65.2% | -$5.72M+31.9% | ||
| $802.32M-19.1% | $821.08M-6.2% | $785.57M-11.3% | $846.78M-12.5% | $991.25M+29.4% | ||
| —— | —— | —— | —— | $0— | ||
| $2.08M-8.4% | $1.54M-49.9% | $2.45M-27.6% | $2.28M-28.4% | $2.27M-18.1% | ||
| $6.88M-71.0% | $29.37M+5,845% | $28.89M+314% | $26.97M+147% | $23.7M+59.2% | ||
| $21.83M-14.5% | $30.67M+30.7% | $28.65M+30.4% | $31.86M+92.6% | $25.52M+71.6% | ||
| -$48.07M+33.4% | -$75.68M-9.3% | -$65.17M+16.7% | -$80.4M+23.0% | -$72.14M+40.4% | ||
| -$48.07M+33.4% | -$75.68M-9.3% | -$65.17M+16.7% | -$80.4M+23.0% | -$72.14M+40.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does NovoCure generate?
- NovoCure (NVCR) generated -$26.9M in operating cash flow over the trailing twelve months.
- What is NovoCure's free cash flow?
- After $21.2M of capital expenditures, NovoCure's free cash flow was -$48.1M over the trailing twelve months, up 33.4% year over year.
- Where does NovoCure's cash flow data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
